Successful Management of Erythema Dyschromicum Perstans Following Topical Ruxolitinib Therapy.
J Drugs Dermatol
; 22(3): 297-299, 2023 Mar 01.
Article
em En
| MEDLINE
| ID: mdl-36877872
ABSTRACT
Erythema dyschromicum perstans (EDP) is a rare cutaneous disorder in which patients develop gray or blue-brown macules or patches on their bodies.1 This condition does not appear to have a gender or age predilection. The diagnosis of EDP is essentially clinical, with histopathology findings being nonspecific. To date, treatment for EDP varies. The use of several therapies, including dapsone, clofazimine, retinoid A, tacrolimus, and ultraviolet light have been reported but with minimal effectiveness.5 We report a case of EDP occurring in a patient following the COVID-19 vaccine that was given topical ruxolitinib with success in treatment. To our knowledge, this is the first report of the use of topical ruxolitinib in treatment of EDP with successful management. J Drugs Dermatol. 2022;22(3) doi10.36849/JDD.7156.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Vacinas contra COVID-19
/
COVID-19
Tipo de estudo:
Diagnostic_studies
Limite:
Humans
Idioma:
En
Revista:
J Drugs Dermatol
Assunto da revista:
DERMATOLOGIA
Ano de publicação:
2023
Tipo de documento:
Article